Innovative Breakthrough! Hemos Bioscience Granted Two More National Invention Patents

Recently, two innovative achievements of Hemos Bioscience have been granted invention patents by the National Intellectual Property Administration, namely: 《 Keratin, for Keratin Gel Dressing for Chronic Wound Repair (Patent No.: ZL202210452908.0) and “A Keratin-Based Iodine-Containing Disinfectant and Its Preparation Method” (Patent No.: ZL202311162315.1). This authorization marks another authoritative recognition of Hemos Bioscience's technological innovation capabilities in the field of recombinant keratin.

Patent One

Keratin, keratin gel dressing for chronic wound healing

 

This patent focuses on the field of biopharmaceutical technology. By optimizing the molecular structure and functional properties of recombinant keratin, we have innovatively developed a gel dressing with highly effective hemostatic, anti-infective, and tissue-regeneration-promoting capabilities. Specifically designed for chronic, hard-to-heal wounds such as diabetic foot ulcers, this dressing offers a comprehensive solution that combines “hemostasis, anti-infection, and tissue repair.”

 

 

Patent No. 2

An iodine-containing disinfectant based on keratin and its preparation method

 

This patent breaks through the functional limitations of traditional disinfectants by employing a synergistic formulation combining elemental iodine, stabilizers, and recombinant keratin, successfully developing a novel disinfectant that simultaneously boasts both high-efficiency antimicrobial activity and tissue-repair capabilities. While rapidly eliminating pathogenic microorganisms, the product significantly accelerates granulation tissue growth, offering a safe and enhanced solution for postoperative wound care and the management of chronic wounds.

 

 

As of now, Hemos Bioscience has obtained more than 40 patents and has established a comprehensive technology system covering the entire chain—from raw material preparation and formulation optimization to functional applications. Its core technologies have expanded into high-value areas such as biomedical materials, medical aesthetic injectable fillers, and functional personal care products, creating a full-industry-chain ecosystem that spans the medical, medical aesthetic, and consumer sectors, thereby laying a solid foundation for diversified business development.

In the future, Hemos Bioscience will continue to increase its R&D investment, deepen its patent layout in the biotechnology field, promote iterative innovation in recombinant keratin technology, accelerate the commercialization of scientific research achievements, and dedicate itself to creating value for human health through more groundbreaking technological breakthroughs.